Google’s informal corporate slogan is “Don’t be evil.” Whole Foods is a Fortune 500 company with a net revenue of 10 billion dollar that prides itself on a commitment to social responsibility. Both companies have pledged to do long-term good in the world, even at the expense of short-term gains, and both are wildly successful.
If corporations can be profitable as a result of their commitments to social justice and corporate ethics, why can’t this doctrine be extended to the pharmaceutical industry? Someday, a company called GoodPharma might reach the Fortune 500 on the basis of a pledge to improve access to medicine, conduct international research trials in accordance with the highest standards of research ethics, engage in research on orphan diseases, publish negative research findings, promptly report information about adverse effects, and generally act as a model for ethical industry practices. If this business model hasn’t been explored, it should be.
Filed Under: OP-EDTagged: Access to Medicine Index, Big pharma, Bill of Health, Corporate Social Responsibility, Ethical Practices, GlaxoSmithKline, GoodPharma, Google, Harvard Law School, Nadia Sawicki, Petrie-Flom Center, Pharma, Physicians, Public Access, Whole Foods Dec 10, 2012